rxstat › Drug prices › Rifampin

Rifampin (Rofact, Rifadin) price in Canada

No current shortage

Source: Health Canada shortage reports · Updated Jul 9, 2026

Rifampin 150 mg capsule costs about $0.85 to $0.92 per capsule on public drug plan price lists across 4 provinces, before the pharmacy's dispensing fee.

Rifampin has no current shortage reported in Canada. It has been in shortage before; the history is below.

Price by province

Strength and formABSKONNBNS
150 mg Capsuleper capsule$0.92not covered$0.87$0.92$0.85$0.88
300 mg Capsuleper capsule$1.45not covered$1.37$1.45$1.34$1.38
Plan coverageNot coveredSpecial approvalCoveredCoveredCovered

Lowest price per unit among each province's covered products, with the brand price where it is notably higher. A dash means the province does not list it.

Detailed price and coverage in your province:

What you'll pay at the pharmacy

These are the prices public drug plans list for the drug itself. At the counter, pharmacies add a dispensing fee and in some provinces a markup, so paying cash costs more, and for cheap generics the fee is often more than the drug. If you have a public or private plan, your share depends on its deductible and co-pay.

Listed products by province

Alberta: 2 products
  • Rofact 150 mg Capsule · VCL
    DIN 00393444 · $0.92/capsule · Not covered
  • Rofact 300 mg Capsule · VCL
    DIN 00343617 · $1.45/capsule · Not covered
Saskatchewan: 2 products
  • Rofact 150 mg Capsule · BAU
    DIN 00393444 · $0.87/capsule · Special approval
  • Rofact 300 mg Capsule · BAU
    DIN 00343617 · $1.37/capsule · Special approval
Ontario: 2 products
  • Rofact 150 mg Capsule · Valeant Canada Ltd.
    DIN 00393444 · $0.92/capsule · Covered
  • Rofact 300 mg Capsule · Valeant Canada Ltd.
    DIN 00343617 · $1.45/capsule · Covered
New Brunswick: 2 products
  • Rofact 150 mg Capsule · BSL
    DIN 00393444 · $0.85/capsule · Covered
  • Rofact 300 mg Capsule · BSL
    DIN 00343617 · $1.34/capsule · Covered
Nova Scotia: 2 products
  • Rofact 150 mg Capsule · BSL
    DIN 00393444 · $0.88/capsule · Covered
  • Rofact 300 mg Capsule · BSL
    DIN 00343617 · $1.38/capsule · Covered

Price sources: Ontario Drug Benefit Formulary (Oct 30, 2026) · Alberta Drug Benefit List and Alberta Blue Cross price list (Nov 1, 2026) · Saskatchewan Drug Plan Formulary (Nov 1, 2026) · New Brunswick Drug Plans Formulary (Nov 1, 2026) · Nova Scotia Pharmacare Formulary (Nov 1, 2026). Other provinces and territories will be added as their public price lists are brought in.

Shortage status

Products affected
0 / 4
Reports on file
20

Shortage history

2023 2024 2025 2026

Shortage history (red bands = periods in shortage).

Reports by product

The DIN is printed on your prescription label.

Resolved
ROFACT
300MG · CAPSULE · BAUSCH HEALTH, CANADA INC.
DIN 00343617 · ended Apr 16, 2024 · Delays in testing at external lab
Avoided
ROFACT
300MG · CAPSULE · BAUSCH HEALTH, CANADA INC.
DIN 00343617 · ended Feb 19, 2024 · Capacity Problem in Production
Avoided
ROFACT
150MG · CAPSULE · BAUSCH HEALTH, CANADA INC.
DIN 00393444 · ended May 30, 2023 · equipment issue in manufacturing
Avoided
ROFACT
300MG · CAPSULE · BAUSCH HEALTH, CANADA INC.
DIN 00343617 · ended Mar 24, 2023 · Delays in outside lab testing
Resolved
ROFACT
300MG · CAPSULE · BAUSCH HEALTH, CANADA INC.
DIN 00343617 · ended Feb 23, 2023 · Shortage of an inactive ingredient or component.
Resolved
ROFACT
150MG · CAPSULE · BAUSCH HEALTH, CANADA INC.
DIN 00393444 · ended Feb 23, 2023 · Shortage of an inactive ingredient or component.
Discontinued
RIFADIN
300MG · CAPSULE · SANOFI-AVENTIS CANADA INC
DIN 02092808
Discontinued
RIFADIN
150MG · CAPSULE · SANOFI-AVENTIS CANADA INC
DIN 02091887
Resolved
RIFADIN
300MG · CAPSULE · SANOFI-AVENTIS CANADA INC
DIN 02092808 · ended Jan 28, 2021
Resolved
RIFADIN
150MG · CAPSULE · SANOFI-AVENTIS CANADA INC
DIN 02091887 · ended Jan 28, 2021
Resolved
ROFACT
150MG · CAPSULE · BAUSCH HEALTH, CANADA INC.
DIN 00393444 · ended Jul 10, 2020 · Shortage of an inactive ingredient or component.
Avoided
ROFACT
150MG · CAPSULE · BAUSCH HEALTH, CANADA INC.
DIN 00393444 · ended Apr 21, 2020 · Demand increase for the drug.

Showing 12 of 20 reports. All reports are on file with Health Canada.

What's happening

There are no active shortage reports for Rifampin. Health Canada has 20 historical reports on file for this drug, so supply has been disrupted before; the change log below shows the history.

Rifampin is classified under “DRUGS FOR TREATMENT OF TUBERCULOSIS” (ATC J04AB).

Recent changes

Common questions

How much does Rifampin cost in Canada?

Rifampin 150 mg capsule costs about $0.85 to $0.92 per capsule on public drug plan price lists across 4 provinces, before the pharmacy's dispensing fee.

Is Rifampin covered by provincial drug plans?

On the public plans' own lists: Alberta: not covered; Saskatchewan: special approval; Ontario: covered; New Brunswick: covered; Nova Scotia: covered. "Special approval" means the plan covers it only for some patients, on a request from the prescriber. "Price list" means the province publishes its price but not its coverage.

When will Rifampin be back in stock in Canada?

Rifampin has no active shortage; supply is normal per Health Canada reports.

Why is Rifampin in shortage?

It isn't currently. Past reports and their reasons are listed above.

What can my pharmacist do about it?

Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.

Email alerts

Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.

Related drugs (drugs for treatment of tuberculosis)

Guides: what to do when your medication is in shortage · how to read shortage reports

Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.